Abstract: The invention generally relates to immunotherapy with chimeric antigen receptor (CAR}- engineered T-cells. In particular, the invention relates immunotherapy with chimeric antigen receptor (CAR)-engineered T-cells to target sub-populations of cancer cells that are characterized by low expression of a cancer cell surface antigen, more particular the invention relates to immunotherapy with chimeric antigen receptor (CAR)-engineered T-cells targeting CD19 (CD19CART) in multiple myeloma, a clonal proliferation of plasma cells.

Abstract: The present invention relates to a nucleic acid molecule, to a kit which comprises the nucleic acid molecule, to methods for detecting fungi in clinical material and for determining the sequence of ribosomal fungal genes, and to kits for carrying out these methods.

Abstract: Oligonucleotides of the sequence listing are used as DNA probes in a method and a kit for detecting a fungal species in clinical material, in order to detect via hybridization DNA segments of fungal DNA extracted from said clinical material.

Abstract: For the detection of fungal cells in clinical material fungal DNA is extracted from whole blood and the extracted fungal DNA is then detected. From this detection, a fungal infection can be concluded. For further diagnosis, the fungal species are then determined from the extracted fungal DNA. The method for extraction of the fungal DNA from whole blood comprises the isolation of predominantly intact fungal cells from the whole blood and the extraction of DNA from the isolated fungal cells. For detection of fungal DNA, at least one segment of the fungal DNA to be detected is amplified, then the amplification products are detected. For further identification of the fungal species, nucleotide sequence segments being characteristic for the fungal species are detected.

Abstract: For the detection of fungal cells in clinical material fungal DNA is extracted from whole blood and the extracted fungal DNA is then detected. From this detection, a fungal infection can be concluded. For further diagnosis, the fungal species are then determined from the extracted fungal DNA. The method for extraction of the fungal DNA from whole blood comprises the isolation of predominantly intact fungal cells from the whole blood and the extraction of DNA from the isolated fungal cells. For detection of fungal DNA, at least one segment of the fungal DNA to be detected is amplified, then the amplification products are detected. For further identification of the fungal species, nucleotide sequence segments being characteristic for the fungal species are detected.

Abstract: A method is presented for detecting resistant fungal cells in clinical material. First, fungus-specific nucleic acids are extracted from clinical material. Then, the fungus-specific nucleic acids are hybridized with hybridization probes directed against nucleic acids segments of azole derivative-resistant fungal cells. Prior to the hybridization a PCR reaction may be performed in which segments of the 14-&agr;-lanosterol demethylase gene are amplified. Primers and probes for the PCR rejection and the hybridization, respectively, are also presented.

Abstract: A method and kit for detecting fungal cells in clinical material utilizing nucleic acid hybridization probes identified as SEQ. ID NO. 9-12.